Low-Dose GLP-1 Beyond Weight Loss: Cardiac, Hepatic, and Metabolic Indications DTC Telehealth Should Track

GLP-1 care is outgrowing the weight loss funnel

For three years, most DTC telehealth GLP-1 programs were built around one outcome.

Weight loss.

That was a reasonable simplification. The drugs work for weight. Patients wanted weight. The funnel converted.

In 2026, that frame is too narrow.

The strongest clinical evidence is now in indications that have little or nothing to do with appetite or scale weight:

cardiovascular event reduction in adults with overweight or obesity and known heart disease
symptom and function improvement in heart failure with preserved ejection fraction (HFpEF)
slower progression of chronic kidney disease in type 2 diabetes
resolution of metabolic dysfunction-associated steatohepatitis (MASH) with reduced fibrosis
a new mechanistic case for low-dose GLP-1 effects on cardiac and hepatic remodeling independent of weight loss

That last finding is the one that should reshape the conversation.

For DTC telehealth teams, the practical question is not "should we still sell weight loss?"

It is "what does the program look like when the science says the medication does more than that?"

This post walks through what the evidence actually shows, what it changes operationally, and what marketing should and should not claim in 2026.

The evidence base in one map

A useful starting point is to separate what is approved, what is published, and what is preprint or emerging.

Indication	Trial	Dose	Headline result	Status
Cardiovascular event reduction in overweight or obesity with established CVD, no diabetes	SELECT	Semaglutide 2.4 mg weekly	20% reduction in MACE	FDA-approved indication (Wegovy)
HFpEF symptoms in obesity, with or without T2D	STEP-HFpEF, STEP-HFpEF DM	Semaglutide 2.4 mg weekly	Significant improvement in KCCQ, exercise function, diuretic reduction	Published, label updated
Chronic kidney disease in T2D	FLOW	Semaglutide 1.0 mg weekly	24% reduction in primary kidney outcome, 20% lower all-cause mortality	Published, label updated
MASH with F2-F3 fibrosis	ESSENCE phase 3	Semaglutide 2.4 mg weekly	62.9% MASH resolution vs 34.3% placebo at 72 weeks	Accelerated FDA approval, Wegovy label
Direct cardiac and hepatic remodeling	Pre-clinical, low-dose semaglutide	30 nmol/kg twice weekly in rat HFpEF model	Reduced fibrosis and lipotoxicity, independent of weight loss	Preprint, mechanistic
OSA in adults with obesity	SURMOUNT-OSA	Tirzepatide	Significant AHI reduction	FDA-approved (Zepbound)

Two things stand out.

First, none of these indications is "weight loss" in the marketing sense. They are diseases.

Second, the doses differ. SELECT, STEP-HFpEF, and ESSENCE used 2.4 mg semaglutide. FLOW used 1.0 mg. The HFpEF preprint used a low dose in animals to make a mechanistic case.

That matters when patients start asking why "microdosing" is being marketed as longevity, and whether smaller doses can deliver the same disease-modifying effects.

Treatments

Example GLP-1 Treatments We Can Launch

View all

What SELECT changed about cardiovascular positioning

The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes.

Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo.

The trial also showed:

a 22% lower risk of renal outcomes
a 73% reduction in incident diabetes
significant reductions in hospital admissions
weight loss that did not fully explain the cardiovascular benefit

The clinical and marketing implications are not the same.

Clinically, this is one of the strongest cardiovascular outcomes datasets in modern obesity medicine.

For marketing, the temptation is to say "our GLP-1 program prevents heart attacks." That language overshoots what an individual patient can be told, and what the FDA-approved indication supports.

A defensible DTC posture:

the medication has an FDA-approved indication for cardiovascular event reduction in eligible adults with overweight or obesity and known CVD without diabetes
the program can support patients who meet those criteria with appropriate provider review
claims at the individual patient level should be framed as risk reduction in a population, not personal guarantee

What STEP-HFpEF changed about heart failure care

STEP-HFpEF and STEP-HFpEF DM tested semaglutide 2.4 mg in adults with obesity-related heart failure with preserved ejection fraction, with and without type 2 diabetes.

The results were strong:

significant improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score
improved exercise function on the six-minute walk test
a 71% reduction in new loop diuretic initiation
weight loss
better outcomes in patients on loop diuretics at baseline

This is a population most DTC programs do not currently serve well.

A weight loss intake form does not typically capture:

diagnosed heart failure
ejection fraction
diuretic use
functional class
recent hospitalization
cardiology follow-up

For programs that want to take HFpEF seriously, intake needs to ask. Provider review needs to coordinate with cardiology. The marketing needs to be specific, not generic.

A weight loss patient who happens to have HFpEF should not be silently sold a generic weight loss program. The science is clear that semaglutide 2.4 mg is meaningful for their condition. The program design should reflect that.

What FLOW changed about kidney care

The FLOW trial enrolled 3,533 adults with type 2 diabetes and chronic kidney disease at varying severity, on a renin-angiotensin system inhibitor.

The dose was once-weekly semaglutide 1.0 mg.

Results:

24% reduction in the primary composite kidney outcome
18% lower risk of cardiovascular events
29% lower risk of cardiovascular death
20% lower risk of death from any cause
benefit across CKD severity strata

Important nuance: the 1.0 mg dose is the diabetes dose, not the 2.4 mg obesity dose.

That distinction matters for telehealth programs. A patient with T2D and CKD on a 1.0 mg regimen for kidney protection is a different patient than one on 2.4 mg for weight loss with kidney monitoring. The intake, provider workflow, and labs follow different protocols.

For more on the broader lab workflow, see Telehealth Lab Workflow Design: Preventing Drop-Off Between Order, Completion, and Review.

What ESSENCE changed about liver disease

ESSENCE is the phase 3 trial of semaglutide 2.4 mg in adults with biopsy-confirmed MASH and F2 or F3 fibrosis.

At the 72-week interim, the results were striking:

MASH resolution without fibrosis worsening: 62.9% vs 34.3% on placebo
one-stage or greater fibrosis reduction without MASH worsening: 36.8% vs 22.4% on placebo
combined MASH resolution and fibrosis reduction: 32.7% vs 16.1% on placebo
10.5% body weight reduction vs 2.0% on placebo

In August 2025, FDA granted accelerated approval to the Wegovy formulation for MASH with moderate to advanced fibrosis based on the interim ESSENCE data.

At EASL 2026, Novo Nordisk presented additional hepatic safety, menopausal women, and Japanese population analyses, deepening the regulatory and clinical case.

For DTC telehealth teams, this is not a small footnote.

MASH is widely underdiagnosed, often invisible to the patient, and increasingly relevant in the same population that GLP-1 programs already see (adults with obesity, type 2 diabetes, metabolic syndrome).

The operational question is whether your program is ready to:

screen for fibrosis risk (FIB-4 score, ELF test, vibration-controlled transient elastography referral)
coordinate with hepatology for biopsy or imaging confirmation
document MASH appropriately for provider review and billing
distinguish MASH-indicated care from weight loss care in marketing language

The 2025 low-dose preprint and what it might mean

A 2025 bioRxiv preprint titled "Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss" is the most provocative new signal in the category.

The design:

ten-week-old male ZSF1 obese rats with spontaneous HFpEF
low-dose semaglutide at 30 nmol/kg twice weekly for 16 weeks
single-cell RNA sequencing of heart and liver
cardiac, hepatic, and plasma proteomics

The finding:

attenuated cardiac and hepatic fibrosis
reverse lipid transport effects
benefit that did not depend on weight loss

The authors note: "Findings support the investigation of lower GLP-1RA dosing in HFpEF and other cardiovascular conditions, including in non-obese patients."

Two things matter for DTC telehealth.

First, this is a preprint and an animal model. It is hypothesis-generating, not practice-changing.

Second, it is the most credible mechanistic case yet that lower-than-label doses might do something clinically useful.

If human trials confirm any of it, the entire microdose conversation moves from wellness marketing into a real clinical category.

For now, the right posture is to track it, not market on it.

What this changes inside intake

A weight loss intake is not enough.

If your program serves any of these populations, intake should capture more.

Cardiovascular history

diagnosed coronary artery disease, prior MI, prior stroke, peripheral arterial disease
heart failure diagnosis and type (HFrEF vs HFpEF)
ejection fraction if known
current cardiology follow-up
loop diuretic use
recent hospitalization for cardiovascular cause
NYHA functional class if known

Renal history

known CKD diagnosis and stage
most recent eGFR and urine albumin-to-creatinine ratio (UACR)
current renin-angiotensin system inhibitor use (ACE inhibitor or ARB)
nephrology follow-up

Hepatic history

known MASH, MASLD, or fatty liver diagnosis
prior FIB-4 score, ELF test, or elastography
liver biopsy history
hepatology follow-up
viral hepatitis history
alcohol use screening

Sleep and respiratory

diagnosed OSA
prior sleep study results
CPAP use and adherence

Capturing this is not bureaucracy. It is the input that allows provider review to be honest about which indication, which dose, and which monitoring plan fits the patient.

What this changes inside provider review

Provider review for a "weight loss" program is different from provider review for cardiometabolic care.

A program that wants to serve any of the non-weight indications should equip providers to:

distinguish weight loss intent from disease-modification intent
document the relevant indication clearly in the chart
select the dose appropriate to the indication (1.0 mg in CKD, 2.4 mg in CVD, HFpEF, MASH, weight loss)
order or request the relevant labs and imaging
coordinate with cardiology, nephrology, or hepatology
escalate cases that need specialist confirmation
monitor side effects in cardiometabolic populations that may differ from a typical weight loss profile

Provider templates should include:

structured fields for ejection fraction, eGFR, UACR, FIB-4
a treatment rationale field that names the indication
a referral path for specialist coordination
a monitoring schedule that reflects the indication

Without this, programs will end up treating disease-state patients as if they were generic weight loss patients. That is a clinical and compliance risk.

For broader context on provider workflow, see Provider Capacity Planning in Telehealth: Grow Without Creating Review Backlogs.

What this changes inside labs and monitoring

A weight loss lab panel is usually thin: a CBC, a CMP, lipids, an HbA1c, maybe a thyroid panel.

A cardiometabolic program needs more.

Baseline labs for expanded indications

Indication	Suggested baseline assessment
CVD risk and SELECT-like care	Lipids, HbA1c, eGFR, BP, ECG when clinically indicated
HFpEF	NT-proBNP or BNP, recent echocardiogram, six-minute walk if feasible, KCCQ baseline
CKD in T2D	eGFR, UACR, current ACEi or ARB confirmation, potassium
MASH	FIB-4, ELF test where available, vibration-controlled transient elastography referral when indicated, AST, ALT, platelets
OSA	STOP-BANG, Epworth, HSAT referral if positive screen

These are not all things the platform needs to perform in-house. Many can be ordered through partners, referred to local labs, or coordinated with the patient's primary care or specialist.

What matters is that the program collects the data needed to support the indication and document the rationale.

What this changes inside marketing

This is where the most discipline is needed.

The claims a brand can defensibly make in 2026 fall into three tiers.

Tier 1: Approved indications and trial results, accurately described

"Semaglutide 2.4 mg has an FDA-approved indication for reducing the risk of major cardiovascular events in eligible adults with overweight or obesity and established cardiovascular disease without diabetes."
"Semaglutide is FDA-approved for MASH with moderate to advanced fibrosis, based on the ESSENCE trial."
"Tirzepatide is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity."

These are sound when used accurately and in context.

Tier 2: Supporting science framed as population-level evidence, not individual promise

"In the STEP-HFpEF trials, patients on semaglutide 2.4 mg saw significant improvements in heart failure symptoms and exercise function."
"In the FLOW trial, semaglutide 1.0 mg reduced major kidney outcomes in adults with T2D and CKD by 24%."

Use these in clinical and educational contexts. Avoid them on top-of-funnel ad copy where the implied promise becomes "this drug will protect your heart."

Tier 3: Off-limits without strong scoping

"Microdose semaglutide for healthspan."
"GLP-1s prevent Alzheimer's."
"Low-dose GLP-1 protects your heart without weight loss."

The Alzheimer's claim is now contradicted by the EVOKE and EVOKE+ phase 3 results, which were negative. The low-dose mechanistic claim is supported by a preprint in animals only. The healthspan claim has no robust human evidence.

Any of these in marketing copy is a FTC and FDA risk. Several DTC brands have already attracted scrutiny for similar language.

For broader context, see Marketing Your GLP-1 Program in 2026 and Running GLP-1 Ads in 2026: What Telehealth Teams Need to Know.

A decision framework for which indications your program should support

Most DTC teams cannot meaningfully support every indication on day one.

A useful framework:

Indication	Difficulty to support well	When to add
Weight loss with no comorbidity flag	Low	Most programs already do this
Weight loss with cardiometabolic risk capture	Low to medium	High priority for all 2026 programs
Cardiovascular event reduction (SELECT population)	Medium	When provider workflow can document CVD history and coordinate with cardiology
OSA in adults with obesity	Medium	When the program supports HSAT and CPAP coordination, see the OSA program post
MASH with F2-F3 fibrosis	Medium to high	When the program can do fibrosis screening and hepatology coordination
CKD in T2D	High	When the program has diabetes management depth and nephrology partnership
HFpEF in obesity	High	When the program has cardiology partnership and HF documentation
"Longevity" or healthspan as a marketing wrapper	Not yet defensible	Not until human evidence supports the claim

A reasonable 2026 path:

every program should at least capture cardiometabolic risk in intake, even if it does not treat to all indications
programs ready to expand should pick one expansion at a time (CVD, OSA, or MASH are the most accessible)
CKD and HFpEF expansions require deeper clinical scaffolding and are good fits for programs with a strong primary care or cardiometabolic foundation

For broader specialty expansion decisions, see Telehealth Specialty Expansion: How to Decide the Next Program After GLP-1, Hair Loss, and Sexual Health.

A readiness checklist for expanding beyond weight loss

Use this as a 60 to 90 day planning aid.

Strategy and scope

Indication selection - Which non-weight indication is the program adding first?
Eligibility criteria - Which patient profile qualifies, based on the trial population?
Out-of-scope criteria - Which patient situations trigger referral out of the program?
Specialist partnerships - Which cardiology, nephrology, or hepatology partners support the program?
Dose policy - Which dose corresponds to which indication, documented for providers?

Intake and screening

Cardiovascular history capture - CAD, MI, stroke, PAD, HF, EF, NYHA class.
Renal history capture - CKD stage, eGFR, UACR, ACEi or ARB use.
Hepatic history capture - Fatty liver, MASH, FIB-4, prior biopsy.
Sleep history capture - OSA diagnosis, CPAP use, STOP-BANG and Epworth.
Lab review path - Which labs are required at baseline by indication?
Validated instruments - KCCQ, Epworth, STOP-BANG, PHQ-9 where relevant.

Provider workflow

Indication-specific templates - Cardiac, renal, hepatic, OSA notes.
Indication rationale field - Free-text and structured tagging.
Dose routing - Provider can select the dose appropriate to the indication.
Specialist referral path - Visible inside the chart.
Monitoring schedule by indication - Cadence and labs differ.
Side-effect protocol by population - Older adults, HFpEF, CKD differ.

Billing and packaging

Bundle pricing - Separate bundles for weight loss vs cardiometabolic care.
Insurance posture - Cash-pay, hybrid, or insurance for the new indication.
Refund and pause policy - Clear rules when an indication changes mid-program.
Patient-facing scope statement - What the program treats and does not treat.

Marketing and content

Approved-indication copy - Trial-accurate language at landing page and ad layer.
Avoidance list - Claims that are not defensible (healthspan, Alzheimer's, generic "heart protection").
Education library - Patient-facing explainers for each new indication.
FTC and FDA review - Marketing claims reviewed by qualified counsel.
Disclosure of off-label or investigational use - If applicable, clearly stated.

Compliance and risk

Documentation standards - Indication, dose, monitoring, and rationale captured in the chart.
Audit log - Decisions and orders tracked.
HIPAA review - Specialist data exchange and partner contracts.
State licensure mapping - Where the program is active for each indication.

Metrics to track for non-weight indications

The dashboard cannot be the same as a weight loss dashboard.

Metric	Why it matters
Cardiometabolic risk captured at intake (% of completed intakes)	Foundation for all expansion
Indication tagged in chart (% of treated patients)	Documentation health
Specialist referral completion rate	Coordination quality
Lab completion rate (FIB-4, eGFR, UACR, NT-proBNP)	Clinical depth
Dose alignment to indication (% concordance)	Provider workflow health
Symptom outcomes (KCCQ, Epworth, PHQ-9 where relevant)	Real-world outcomes
Time to indication-specific follow-up	Continuity of care
Marketing claim audit pass rate	Compliance risk

For broader operations dashboards, see Weekly Telehealth Ops Dashboard: 12 Metrics Leadership Should Review.

Common mistakes when expanding beyond weight loss

A few patterns to avoid.

Marketing one indication, treating another

Some brands market "heart protection" but treat patients with the same weight loss workflow. That mismatch is a compliance and clinical risk.

Using the wrong dose for the indication

Semaglutide 1.0 mg is the diabetes and CKD dose. 2.4 mg is the obesity, HFpEF, MASH, and CVD-in-obesity dose. Dose selection is part of indication selection.

Skipping the labs

You cannot defensibly serve MASH without fibrosis screening. You cannot defensibly serve CKD without eGFR and UACR. You cannot defensibly serve HFpEF without functional and structural cardiac data.

Treating the low-dose preprint as practice-changing

It is a preprint. It is mechanistic. It is in rats. It is interesting. It is not yet evidence to base marketing or clinical decisions on.

Ignoring sarcopenia in older cardiometabolic patients

Older patients with HFpEF, CKD, or MASH are the populations where lean mass loss matters most. A muscle preservation protocol belongs alongside any expansion.

Promising what EVOKE just disproved

The EVOKE and EVOKE+ phase 3 trials in 2026 showed no benefit of oral semaglutide for early Alzheimer's. Brands using cognitive or dementia claims should remove them now.

How this connects to the rest of the platform

A cardiometabolic-aware GLP-1 program is not a separate brand.

It is the same platform with more capability:

the intake captures more
the provider review documents more
the labs and imaging workflow integrates with more partners
the patient portal shows indication-specific education and check-ins
the CRM tags patients by indication
the billing engine supports indication-specific bundles
the support team has scripts for each indication

If you already have a strong GLP-1 program, expanding into one of the non-weight indications usually does not require rebuilding the platform.

It requires structuring the data, the templates, and the language so that each indication is treated as itself, not as a marketing wrapper around the same weight loss flow.

For context on the broader product map, see New GLP-1 Products in 2026: The Telehealth Product Map and Next-Generation GLP-1s in 2026: How Telehealth Teams Should Prepare for CagriSema, Retatrutide, and New Oral Options.

Final takeaways

The GLP-1 evidence base in 2026 is no longer about scale weight alone.

The DTC telehealth teams that grow from here will:

treat cardiovascular, renal, hepatic, and sleep indications as real programs, not marketing language
match dose to indication, not just to patient preference
expand intake to capture cardiometabolic context
equip providers with indication-specific templates and referral paths
build lab and specialist coordination into the workflow
speak about trial evidence accurately at every layer of marketing
track the low-dose preprint and emerging human data without overclaiming
remove cognitive and Alzheimer's claims that are no longer supported
bundle pricing and education by indication, not by molecule

The brands that keep selling weight loss as a single funnel will still have a business.

The brands that build a cardiometabolic care platform will have the more durable one.

The science is moving in that direction.

The operational model should move with it.

Sources for the trial evidence cited:

SELECT trial: Semaglutide 2.4 mg and cardiovascular outcomes in overweight or obesity with established CVD (Cleveland Clinic newsroom summary, JACC subgroup analysis)
STEP-HFpEF pooled analysis: Semaglutide 2.4 mg in obesity-related HFpEF (NEJM, European Heart Journal pooled analysis)
FLOW trial: Semaglutide 1.0 mg in T2D and CKD (NEJM, ADA press release)
ESSENCE trial: Semaglutide 2.4 mg in MASH with F2-F3 fibrosis (phase 3 trial coverage, EASL 2026 update, weight-dependent and -independent secondary analysis)
Low-dose GLP-1 in HFpEF, animal mechanistic study (bioRxiv preprint)
EVOKE and EVOKE+ trials in early Alzheimer's disease (The Lancet, Clinical Trials Arena coverage)